Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease - Results of the Study Assessing Goals in the Elderly (SAGE)

被引:218
作者
Deedwania, Prakash
Stone, Peter H.
Merz, C. Noel Bairey
Cosin-Aguilar, Juan
Koylan, Nevres
Luo, Don
Ouyang, Pamela
Piotrowicz, Ryszard
Schenck-Gustafsson, Karin
Sellier, Philippe
Stein, James H.
Thompson, Peter L.
Tzivoni, Dan
机构
[1] Univ Calif San Francisco, VACCHCS, Sch Med, Fresno, CA 93703 USA
[2] VACCHCS, Fresno, CA USA
[3] Brigham & Womens Hosp, Boston, MA 02115 USA
[4] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[5] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90048 USA
[6] Hosp La Fe, Ctr Invest, E-46009 Valencia, Spain
[7] Istanbul Univ, Istanbul Fac Med, Istanbul, Turkey
[8] Pfizer Inc, New York, NY USA
[9] Johns Hopkins Univ, Johns Hopkins Bayview Med Ctr, Baltimore, MD USA
[10] Inst Kardiol, Warsaw, Poland
[11] Karolinska Univ Hosp, Stockholm, Sweden
[12] Hop Broussais, APHP, HEGP, F-75674 Paris, France
[13] Univ Wisconsin, Sch Med, Madison, WI 53706 USA
[14] Univ Western Australia, Perth, WA 6009, Australia
[15] Sir Charles Gairdner Hosp, Perth, WA 6009, Australia
[16] Shaare Zedek Med Ctr, Jerusalem, Israel
关键词
atherosclerosis; electrocardiography; hypercholesterolemia; ischemia; statins;
D O I
10.1161/CIRCULATIONAHA.106.654756
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Background - Clinical trials have demonstrated that, compared with placebo, intensive statin therapy reduces ischemia in patients with acute coronary syndromes and in patients with stable coronary artery disease. However, no studies to date have assessed intensive versus moderate statin therapy in older patients with stable coronary syndromes. Methods and Results - A total of 893 ambulatory coronary artery disease patients (30% women) 65 to 85 years of age with >= 1 episode of myocardial ischemia that lasted >= 3 minutes during 48-hour ambulatory ECG at screening were randomized to atorvastatin 80 mg/d or pravastatin 40 mg/d and followed up for 12 months. The primary efficacy parameter (absolute change from baseline in total duration of ischemia at month 12) was significantly reduced in both groups at month 3 and month 12 (both P < 0.001 for each treatment group) with no significant difference between the treatment groups. Atorvastatin-treated patients experienced greater low-density lipoprotein cholesterol reductions than did pravastatin-treated patients, a trend toward fewer major acute cardiovascular events (hazard ratio, 0.71; 95% confidence interval, 0.46, 1.09; P = 0.114), and a significantly greater reduction in all-cause death (hazard ratio, 0.33; 95% confidence interval, 0.13, 0.83; P = 0.014). Conclusions - Compared with moderate pravastatin therapy, intensive atorvastatin therapy was associated with reductions in cholesterol, major acute cardiovascular events, and death in addition to the reductions in ischemia observed with both therapies. The contrast between the therapies' differing efficacy for major acute cardiovascular events and death and their nonsignificant difference in efficacy for reduction of ischemia suggests that low-density lipoprotein cholesterol lowering thresholds for ischemia and major acute cardiovascular events may differ. The Study Assessing Goals in the Elderly (SAGE) demonstrates that older men and women with coronary artery disease benefit from intensive statin therapy.
引用
收藏
页码:700 / 707
页数:8
相关论文
共 22 条
[1]
Andrews TC, 1997, CIRCULATION, V95, P324
[2]
Intensive versus moderate lipid lowering with statins after acute coronary syndromes [J].
Cannon, CP ;
Braunwald, E ;
McCabe, CH ;
Rader, DJ ;
Rouleau, JL ;
Belder, R ;
Joyal, SV ;
Hill, KA ;
Pfeffer, MA ;
Skene, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) :1495-1504
[3]
VARIABILITY OF EPISODIC ST SEGMENT DEPRESSION IN CHRONIC STABLE ANGINA - IMPLICATIONS FOR INDIVIDUAL AND GROUP TRIALS OF THERAPEUTIC EFFICACY [J].
CELERMAJER, DS ;
SPIEGELHALTER, DJ ;
DEANFIELD, M ;
DEANFIELD, JE .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1994, 23 (01) :66-73
[4]
Gender differences in the management and clinical - Outcome of stable angina [J].
Daly, C ;
Clemens, F ;
Sendon, JLL ;
Tavazzi, L ;
Boersma, E ;
Danchin, N ;
Delahaye, F ;
Gitt, A ;
Julian, D ;
Mulcahy, D ;
Ruzyllo, W ;
Thygesen, K ;
Verheugt, F ;
Fox, KM .
CIRCULATION, 2006, 113 (04) :490-498
[5]
European guidelines on cardiovascular disease prevention in clinical practice -: Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice [J].
De Backer, G ;
Ambrosioni, E ;
Borch-Johnsen, K ;
Brotons, C ;
Cifkova, R ;
Dallongeville, J ;
Ebrahim, S ;
Faergeman, O ;
Graham, I ;
Mancia, G ;
Cats, VM ;
Orth-Gomér, K ;
Perk, J ;
Pyörälä, K ;
Rodicio, JL ;
Sans, S ;
Sansoy, V ;
Sechtem, U ;
Silber, S ;
Thomsen, T ;
Wood, D .
EUROPEAN HEART JOURNAL, 2003, 24 (17) :1601-1610
[6]
Effect of aggressive versus moderate lipid-lowering therapy on myocardial ischemia: The rationale, design, and baseline characteristics of the Study Assessing Goals in the Elderly (SAGE) [J].
Deedwania, PC .
AMERICAN HEART JOURNAL, 2004, 148 (06) :1053-1059
[7]
SILENT ISCHEMIA DURING DAILY LIFE IS AN INDEPENDENT PREDICTOR OF MORTALITY IN STABLE ANGINA [J].
DEEDWANIA, PC ;
CARBAJAL, EV .
CIRCULATION, 1990, 81 (03) :748-756
[8]
Golomb Beatrice Alexandra, 2005, Expert Opin Drug Saf, V4, P389, DOI 10.1517/14740338.4.3.389
[9]
SILENT ST SEGMENT DEVIATIONS AND EXTENT OF CORONARY-ARTERY DISEASE [J].
KUNKES, SH ;
PICHARD, AD ;
SMITH, H ;
GORLIN, R ;
HERMAN, MV ;
KUPERSMITH, J .
AMERICAN HEART JOURNAL, 1980, 100 (06) :813-820
[10]
Intensive lipid lowering with atorvastatin in patients with stable coronary disease [J].
LaRosa, JC ;
Grundy, SM ;
Waters, DD ;
Shear, C ;
Barter, P ;
Fruchart, J ;
Gotto, AM ;
Greten, H ;
Kastelein, JJP ;
Shepherd, J ;
Wenger, NK .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (14) :1425-1435